Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Towards Covid-19 TMPRSS2 enzyme inhibitors and antimicrobial agents: Synthesis, antimicrobial potency, molecular docking, and drug-likeness prediction of thiadiazole-triazole hybrids

H.R.M. Rashdan, A.H. Abdelmonsef

Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Institute, Dokki, Cairo 12622, Egypt
Chemistry Department, Faculty of Science, South Valley University, 83523 Qena, Egypt

1. Introduction

Coronavirus 2019 (Covid-19) is the major cause of global public health problems [1,2]. Coronavirus is an infectious disease caused by SARS-Cov-2 virus [3]. The present need is to identify new antiviral therapeutic agents for Covid-19, which is why TMPRSS2 was selected as a drug target for Covid-19 as it plays a critical role in the propagation of disease. Heterocycles have always been regarded as the basic bedrock of the most modern biomedical and medicinal chemical research. Moreover, microbial infections are still among the major causes of death among the world’s population due to increased bacterial antibiotic resistance phenomena and the development of resistance to chemotherapeutics. For these reasons, there is an urgent need to design and synthesize new antimicrobial agents.

1,3,4-Thiadiazole analogues 3 and 4 were synthesised via the reaction of 1-(5-methyl-1-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazole-4-yl)ethanone 2 with vanillin or thiophene-2-carboxaldehyde, respectively through chalcone reaction. Compounds 3 and 4 were submitted to react with thiosemicarbazide affording 5-(4-hydroxy-3-methoxyphenyl)-3-(5-methyl-1-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazole-4-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (5) give 3-(5-methyl-1-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazole-4-yl)-5-(thiophene-2-yl)-4,5 dihydro-1H-pyrazole-1-carbothioamide (6), respectively. The letters were reacted with N-(4-chlorophenyl)-2-oxopropaneydrazonoyl chloride to give compounds 7 and 8. The chemical compositions of the novel compounds were affirmed by spectral and microanalytical data. Meanwhile, all the newly synthesized compounds have been screened for their ability to prevent the proliferation of different pathogens named Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, Staphylococcus aureus, and Candida albicans in vitro. Additionally, the potency of the newly synthesized compounds to be anti-COVID-19 candidates was studied through a molecular docking study. The newly prepared molecules 2–8 were studied in silico against transmembrane serine protease 2 (TMPRSS2) to identify their potential therapeutic activity against Coronavirus. Moreover, the drug-likeness of the compounds was tested theoretically by ADMET studies. Compound 8 exhibited a better binding affinity (-9.1 kcal/mol) against the target enzyme TMPRSS2. Additionally, it respects Lipinski’s rule of five and has acceptable ADMET properties, indicating that compound 8 could be interesting for the treatment of Covid-19.

© 2022 Elsevier B.V. All rights reserved.
2. Results and discussion

2.1. Chemistry

1-(5-methyl-1-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazol-4-yl) ethan-1-one (2) was allowed to react with vanillin or thiophene-2-carboxaldehyde in the presence of aqueous sodium hydroxide to produce the chalcones 3 and 4, respectively. Chemical structures of 3 and 4 were inferred from correct spectral and microanalytical data. As an authentic sample, $^1$H NMR spectrum of compound 3 showed multiple signals 6.70–7.82 ppm for the aromatic hydrogen, and the proton of (CH=CH) revealed doublet signal at 8.22 ppm for the proton of (CH=C) and showed a singlet signal at 9.52 ppm for the proton of OH group. Compounds 3 and 4 were submitted to react with thiosemicarbazide in boiling ethanolic sodium hydroxide to give 5-(4–hydroxy-3-methoxyphenyl)-3-(5-methyl-1-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazol-4-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (5) 3-(5-methylthio)-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazol-4-yl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (6) The latter were reacted with N-(4-chlorophenyl)-2-oxopropaneydroxynal chloride in boiling ethanol containing catalytic amount of triethylamine gave 4-(1-(5-(4-chlorophenyl)- diazenyl)-4-methylthiazol-2-yl)-3-(5-methyl-1-(5-(methylthio)-13,4-thiadiazol-2-yl)-1H-1,2,3-triazol-4-yl)-4,5-dihydro-1H-pyrazol-5-yl)-2-methoxyphenol (7) and 2-(4-(1-(4-(4-chlorophenyl)- diazenyl)-4-methylthiazol-2-yl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)-5-methyl-1H-1,2,3-triazol-1-yl)-5-(methylthio)-1,3,4-thiadiazole (8) (Scheme 1). For instance, $^1$H NMR spectrum of compound 8 showed doublet of doublet signal at 3.65 ppm for CH$_2$ (pyraz), doublet of doublet signal at 4.01 ppm for CH$_3$ (pyraz), and doublet of doublet signal at 5.52 ppm for CH (pyraz). The structure of compound 8 was also confirmed by its mass spectrum (m/z (599)) [M$^+$] (see Experimental Part).

2.2. Antimicrobial activity

The up growing chemotherapeutic resistance of various microbial pathogens had been considered the most significant clinical problem globally. Consequently, investigation of new organic compounds which could be derived from active groups to serve as wide-spectrum antimicrobials could contribute to compacting such challenges. In the current study, the antimicrobial potency of five newly synthesized compounds against some microbes was detected. The results revealed that compound 8 exhibited antimicrobial activity against all the tested microbes. The toxicity of the other tested compounds was noticed and there were different considerable activities observed against gram-negative bacteria and yeast. The MIC of the tested compound was also listed, as shown in Table 1.

It was worth noting that MIC is defined as the average of the lowest concentrations with no observable growth of microorganisms. Compound 8 revealed a considerable broad spectrum of antimicrobial activities against all strains of the tested pathogens with low concentrations which ranged from 5 to 10 µg/mL; Compound 8 exhibited significant antimicrobial activity against Pseudomonas aeruginosa at the concentration lower than the standard drug Ciprofloxacin. Likewise, Compound 2 provided MIC value at low concentration toward Pseudomonas aeruginosa and Staphylococcus aureus while it showed a relatively higher MIC concentration against Escherichia coli. Although compound 3 had a MIC value at low concentrations toward Bacillus subtilis, Staphylococcus aureus, and Candida albicans, it showed a relatively higher MIC concentration against E. coli and Pseudomonas aeruginosa. Compound 4 provided MIC value at low concentration toward Candida albicans and high MIC concentration against Bacillus subtilis, Staphylococcus aureus, and Candida albicans. Other tested organisms could be resistent to it even at high concentrations. Further, MIC was observed at high concentrations against Pseudomonas aeruginosa, and at low concentrations against E. coli Bacillus subtilis, Staphylococcus aureus, and Candida albicans for compound 6. This study revealed that the antimicrobial activity of the tested new derivatives displayed potent antibacterial and antifungal activities.

2.3. In silico docking study and ADMET analysis

In the current study, the ability of the newly prepared molecules to inhibit Covid-19 TMPRSS2 was calculated by the molecular docking approach. The compounds have high binding affinities against TMPRSS2 enzyme ranging from – 9.1 to –5.5 kcal/mol, which is better achieved using compound 8.
Table 1
Antimicrobial activity and minimum inhibitory concentration (MIC) of the synthesized derivatives.

| Sample No. | Minimum Inhibitory Concentration (MIC, µg/mL) |
|------------|-----------------------------------------------|
|            | Escherichia coli | Pseudomonas aeruginosa | Bacillus subtilis | Staphylococcus aureus | Candida albicans |
| 2          | 160              | 40                        | ND              | 40                        | ND              |
| 3          | 120              | 160                      | 20              | 40                        | 20              |
| 4          | ND               | ND                        | 80              | 80                        | 20              |
| 5          | 40               | 60                        | ND              | ND                        | ND              |
| 6          | 40               | 160                      | 40              | 20                        | 20              |
| 7          | 30               | 40                        | 120             | ND                        | 20              |
| 8          | 30               | 10                        | 10              | 7                         | 5               |
| Ciprofloxacin | 5               | 7                         | 2.5             | 1.25                       | ND              |
| Nystatin   | ND               | ND                        | ND              | ND                        | 5               |

Ciprofloxacin and Nystatin were used as standard drugs as control, ND: not determined.

Table 2
The binding energy values of the docked compounds 2–8 against TMPRSS2.

| Binding Energy (kcal/mol) | Docked complex (amino acid–ligand interactions) | Distance (Å) |
|--------------------------|-----------------------------------------------|--------------|
| 2                        | H-bonds TYR243:OH–compound 2                   | 2.92         |
| 3                        | H-bonds TYR243:OH–compound 3                   | 2.82         |
|                          | GLN350:NE2–compound 3                          | 2.91         |
|                          | GLN331:OE1–compound 1                          | 2.15         |
|                          | π–π interactions TRP377–compound 3              | 5.13         |
|                          | TRP377–compound 3                               | 4.36         |
|                          | π–sigma interactions HIS203–compound 3          | 3.65         |
|                          | TRP377–compound 3                               | 3.73         |
| 4                        | H-bonds TYR243:OH–compound 4                   | 2.94         |
| 5                        | H-bonds ARG208:NE–compound 5                   | 2.86         |
| 6                        | H-bonds PRO245:O–compound 5                    | 2.83         |
| 7                        | π–cation interactions LYS68:NZ–compound 6       | 5.28         |
|                          | ARG130:NH1–compound 6                          | 5.34         |
|                          | ARG130:NH2–compound 6                          | 5.52         |
|                          | π–σ interactions GLN283:CG–compound 6           | 3.96         |
| 8                        | π–π interactions PHE66–compound 6               | 4.81         |
|                          | PHE66–compound 6                               | 5.33         |
|                          | π–cation interactions LYS68:NZ–compound 6       | 3.78         |
|                          | π–σ interactions GLN283:CG–compound 6           | 3.78         |

(−9.1 kcal/mol) (Fig. 1). The binding energies and intermolecular interactions with their distances are tabulated in Table 2. The 2D and 3D representations of the binding interactions of the docked compounds 2–8 against TMPRSS2 enzyme are shown in the (Supplementary materials). Compounds 2 and 4 docked with the target through one hydrogen bonding interaction with the residue TYR243 at 2.92 Å. Compound 3 exhibited binding energy (−6.8 kcal/mol) and showed three hydrogen bonding interactions with TYR243, GLN331, and GLN350. Additionally, it formed two π–π and π–σ-sigma interactions with TRP377 and HIS203 at the distances 5.13, 4.36, 3.65, and 3.73 Å, respectively. Compound 6 docked with the residue PRO245 at 2.83 Å. Compound 5 showed binding energy (−7.4 kcal/mol), and formed one hydrogen bond with ARG208. Compound 7 docked with the residue LYS68, ARG130, and GLN283 though three π–cation and one π–σ-sigma interactions, respectively. Finally, compound 8, with the highest binding affinity (−9.1 kcal/mol), exhibited three π–stacked interactions with PHE66, LYS68, and GLN283.

The ADMET predictions were used to calculate the pharmacokinetics properties of the synthesized molecules. As observed in Table 3, all compounds respected the conditions mentioned in Linskis’s rule of five (Ro5) and had acceptable ADMET properties.

The acceptable ranges are as follows: Mol wt.: (130–725);% Human oral absorption: >80% high, <25% low; Donor HB: (0.0–6.0); Accept HB: (2.0–20.0); Predicted BBB permeability (–3 to 12); Predicted Caco cell permeability in nm/s (<25 is poor and >500 is great).

3. Experimental

3.1. Synthesis

3.1.1. Instruments

The reagents used in this work were used without purification. Melting points of the prepared compounds were determined using Griffin apparatus and are uncorrected. The completion of the reactions was mentioned by Thin Layer Chromatography (TLC) technique on aluminium plates coated with silica gel. IR spectra were recorded on Shimadzu 408 and Bruker Vector 22. NMR spectra were run at 500 MHz using TMS as the internal standard. The chemical shifts were measured in ppm (δ) related to TMS (0.00 ppm). MS were recorded on an HP model, Mass 5988 Mass spectrometer at 70 eV. All new compounds were analysed for C, H, and N at Cairo University, Egypt.
Fig. 1. A: (3D), and B: (2D) representations of the binding interactions of the docked compounds 8 against TMPRSS2 (PDB ID: 1z8g).

Table 3
ADMET profile and drug-likeness properties of the docked molecules 2–8.

| Molecular Weight (g/mol) | Caco-2 Permeability (Caco2+) | Human Intestinal Absorption (HIA+) | logp | TPSA | HBA | HBD | N rotatable | N violations | GI absorption | BBB permeant | Carcinogenicity | Bioavailability score |
|-------------------------|------------------------------|-----------------------------------|------|------|-----|-----|-------------|--------------|---------------|--------------|---------------|----------------------|
| 2                       | 255.32                       | 54.56                             | 97.35| 0.57 | 127.10 | 5     | 0     | 3           | 0            | High         | No          | Noncarcinogenic     | 0.55                   |
| 3                       | 389.45                       | 50.55                             | 98.88| 1.44 | 156.56 | 7     | 1     | 6           | 0            | Low          | No          | Noncarcinogenic     | 0.55                   |
| 4                       | 349.45                       | 54.36                             | 98.81| 1.76 | 155.34 | 5     | 0     | 5           | 0            | Low          | No          | Noncarcinogenic     | 0.55                   |
| 5                       | 462.59                       | 50.23                             | 97.32| 2.23 | 127.59 | 10    | 3     | 6           | 0            | Low          | No          | Noncarcinogenic     | 0.55                   |
| 6                       | 422.57                       | 50.84                             | 87.91| 1.65 | 211.98 | 5     | 1     | 5           | 0            | Low          | No          | Noncarcinogenic     | 0.55                   |
| 7                       | 639.17                       | 54.81                             | 98.52| 3.52 | 139.19 | 12    | 1     | 8           | 0            | Low          | No          | Noncarcinogenic     | 0.17                   |
| 8                       | 599.18                       | 54.04                             | 92.75| 3.92 | 219.78 | 8     | 0     | 7           | 0            | Low          | No          | Noncarcinogenic     | 0.55                   |

HBA, number of hydrogen bond acceptors; HBD, number of hydrogen bond donors; logp, logarithm of partition coefficient between n-octanol and water; N rotatable, number of rotatable bonds.
3.1.4. 5-(4-hydroxy-3-methoxyphenyl)-3-[(5-methyl-1-(5- (methylthio))]-1,3,4-thiadiazol-2-yl]-1H-1,2,3-triazole-4-yl)-4,5 dihydro-1H-pyrazole-1-carbothioamido (5)

A mixture of 3-(4-hydroxy-3-methoxyphenyl)-1-(5-methyl-5-(methylthio))-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazole-4-yl)-4,5 dihydro-1H-pyrazole-1-carbothioamido (5).

3.1.5. 3-(5-methyl-1-(5-methylthio))-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazole-4-yl)-5-(thiophen-2-yl)-4,5 dihydro-1H-pyrazole-1-carbothioamido (6)

A mixture of 1-(5-methyl-1-(5-methylthio))-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazole-4-yl)-3-(thiophen-2-yl) prop-2-en-1-one (4).

3.1.6. 4-(1-(5-(4-chlorophenyl)diazeyl)-4-methylthiazol-2-yl)-3- (5-methyl-1-(5-methylthio))-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazole-4-yl)-4,5 dihydro-1H-pyrazol-5-yl)-2-methoxyphenol (7):

A mixture of 5-(4-hydroxy-3-methoxyphenyl)-3-(5-methyl-1-(5-methylthio))-1,3,4-thiadiazol-2-yl)-1H-1,2,3-triazole-4-yl)-4,5 dihydro-1H-pyrazole-1-carbothioamido (5) (2.31 g, 5 mmol) and triethylamine (0.75 mL, 0.5 g, 5 mmol) in ethanol (20 mL) was stirred under reflux for 4 h. The resulting solid was collected and recrystallized to give 7 as yellow solid; yield: 68%; m.p.222–224 °C; FT-IR (KBr, υ cm−1): 3487(OH), 3023 (CH), 1612 (C = N), 1592 (C = C); 1H NMR (DMSO d6, 500 MHz): δ (ppm) 2.24 (s, 3H, CH3). 2.47 (s, 3H, CH3). 2.72 (s, 3H, CH3). 3.65 (dd, 1H, CH2(pyrazol)). 3.81(s, 3H, OCH3). 4.15 (dd, 1H, CH2 (pyrazol)). 5.21 (dd, 1H, CH(pyrazol)). 752–788 (m, 7H, ArHs).

3.2. Antimicrobial activity

Antimicrobial susceptibility and minimum inhibitory concentration (MIC) of the synthesized Thiadiazoles were determined against two Gram-negative bacteria (E. coli ATCC 25955, Pseudomonas aeruginosa ATCC 10145), two Gram-positive bacteria (Bacillus subtilis ATCC 6633 and Staphylococcus aureus NRRL B-767), and unicellular fungi (Candida albicans ATTC 10231). The pathogens under study were provided by Al-Azhar University, Egypt. They were cultivated in Mueller Hinton broth at 35±2 °C for 24 h. The antimicrobial activity and MIC were carried out as described by Qader et al. (2021) [15].

3.3. In silico molecular docking, drug-likeness and toxicity predictions

PyRx—a virtual screening tool with the standard protocol [23] was used to perform the docking process between the target enzyme TMPRSS2 and the newly synthesized compounds.
In search of anti-Covid-19 therapeutics, a new series of thiadiazole-triazole hybrids were synthesized. Meanwhile, the newly synthesized compounds showed potent antimicrobial activities against the tested pathogens, especially compound 8, which showed the highest activity against all the tested microbes at low MIC concentration. Additionally, the ability of these compounds to inhibit Covid-19 TMPRSS2 enzyme was investigated through a structure-based docking study to identify potent anti-Covid-19 drug candidates. It has been observed that compound 8 has the highest binding affinity toward the target enzyme. Therefore, it could be used as a potential therapeutic agent to combat Coronavirus.

Credit authors statement

All the authors designed the manuscript, synthesized the new compounds which were tested for their Covid-19 TMPRSS2 Enzyme Inhibition potency and their antimicrobial potency. Additionally, the authors revised the manuscript and designed it in its final form.

Declaration of Competing Interest

None.

Data for reference

Data will be made available on request.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.molstruc.2022.133659.

References

[1] S. Baloch, M.A. Baloch, T. Zheng, X. Pei, The coronavirus disease 2019 (COVID-19) pandemic, Tohoku J. Exp. Med., 250 (2020) 271–278.
[2] C. Liu, Q. Zhou, Y. Li, L.V. Garner, S.P. Watkins, L.J. Carter, J. Smoot, A.C. Gregg, A.D. Daniels, S. Jervey, et al., Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases, ACS Cent. Sci. (2020), doi:10.1021/acscentsci.0c00272.
[3] A.A. Rabaan, S.H. Al-Ahmed, S. Haque, R. Sah, R. Tiwari, Y.S. Malik, K. Dhama, M.I. Yato, D.K. Bonilla-Aldana, A.J. Rodriguez-Morales, SARS-COV-2, SARS-COV, and MERS-COV: a comparative overview, Inf. Med. Sci., 28 (2020) 174–184.
[4] Rashdan, H.R.M.; Abdelmonsef, A.H.; Abu-Krishta, M.M.; Yousef, T.A. Synthesis and identification of novel potential thiadiazole based molecules containing 1, 2, 3-triazole moiety against COVID-19 main protease through structure-guided virtual screening approach. 2021.
[5] H.R.M. Rashdan, A.H. Abdelmonsef, in silico study to identify novel potential thiadiazole-based molecules as anti-Covid-19 candidates by hierarchical virtual screening and molecular dynamics simulations, Struct. Chem. (2022) 1–13.
[6] H.R.M. Rashdan, I.A. Shehadi, A.H. Abdelmonsef, Synthesis, anticancer evaluation, computer-aided docking studies, and ADMET prediction of 1,2,3-triazolyl-pyridine hybrids as human aurora B kinase inhibitors, ACS Omega 6 (2021), doi:10.1021/acsomega.0c04772.
[7] M. El-Naggar, A.S. Abd El-Ail, S.L.A. El-Naem, M.M. Abdalla, H.R.M. Rashdan, New potent 5a-Reductase and aromatase inhibitors derived from 1,2,3-triazole derivative, Molecules (2020) 25, doi: 10.3390/25030672.
[8] S. Ahmed, H. Tahatci, O. Demir, A. Ece, G.A. Ciftci, S. Boydenc, Design, synthesis, characterization, in vitro and in silico evaluation of novel imidazo [2, 1-b][1, 3, 4] thiadiazoles as highly potent acetylcholinesterase and non-classical carbonic anhydrase inhibitors, Bioorg. Chem. 113 (2021) 105009.
[9] A. Rashdan, M.T. Abdelrahman, M. Abdelraf, H.R.M. Rashdan, Investigation of novel mucorales fungal inhibitors: synthesis, in-silico study and anti-fungal potency of novel class of coumarin-6-sulfonylamido-thiazole and thiadiazole hybrids, ChemistrySelect 7 (2022) e2200691.
[10] H.R.M. Rashdan, I.A. Shehadi, Triazoles synthesis & applications as nonsteroidal aromatase inhibitors for hormone-dependent breast cancer treatment, Heteroatom. Chem. (2022). 2022.
[11] I.A. Shehadi, M. T. Abdelrahman, M. Abdelraof, H.R.M. Rashdan, Solvent-free synthesis, in vitro and in silico studies of novel potential 1, 3, 4-thiadiazole-based molecules against microbial pathogens, Molecules 27 (2022) 342.
[12] H.R.M. Rashdan, M.T. Abdelrahman, I.A. Shehadi, S.S. El-Tanany, B.A. Hemdan, Novel thiadiazole-based molecules as promising inhibitors of black fungus and pathogenic bacteria: in vitro antimicrobial evaluation and molecular docking studies, Molecules 27 (2022) 3613.
[13] H.R.M. Rashdan, A.H. Abdelmonsef, M.M. Abou-Krishta, T.A. Yousef, Synthesis, Identification, Computer-Aided Docking Studies, and ADMET Prediction of Nonsteroidal Benzimidazole-1, 2, 3-triazole Based Molecules as Potential Anticoagulant Agents, Molecules 26 (2021) 7119.
[14] H.R.M. Rashdan, I.A. Shehadi, M.T. Abdelrahman, B.A. Hemdan, Antibacterial activities and molecular docking of novel sulfone bicomponent containing biologically active triazole moiety, Molecules 26 (2021) 4817.
[15] H.R.M. Rashdan, M. El-Naggar, A.H. Abdelmonsef, Synthesis, molecular docking studies and in silico ADMET screening of new heterocycles linked triazole compounds as potent anti-angiogenic cancer agents, Molecules 26 (2021) 1705.
[16] M.T. Salve, S.B. Jadhav Sr, Synthesis, characterization and antiabetic evaluation of sulfonamide in corporated with 1, 3, 4-oxadiazole derivatives, Indian J. Pharm. Educ. Res. 55 (2021) 1145–1150.
[17] L. Gummad, N. Kerru, O. Ebener, P. Awadla, O. Sanni, M.S. Islam, P. Singh, Multicomponent reaction for the synthesis of new 1, 3, 4-thiadiazole-thiazolidine-4-one molecular hybrids as promising antiangiatic agents through α-glucosidase and α-amylase inhibition, Bioorg. Chem. 115 (2021) 105210.
[18] H.R.M. Rashdan, M.M. Farag, M.S. El-Gendy, M.M. Mounier, Toward rational design of novel anti-cancer drugs based on targeting, solubility, and bioavailability ability exemplified by 1,3,4-thiadiazole derivatives synthesized under solvent-free conditions, Molecules (2019) 24, doi:10.3390/molecules2413373.
[19] Abd El-Dayem, N.S. Synthesis and in vitro antiproliferative evaluation of new synthesized 1, 3, 4-thiadiazole-based heterocycles.
[20] H.R.M. Rashdan, A. Abdel-Aziem, D.H. El-Naggar, S. Nabil, Synthesis and biological evaluation of some new pyridines, isoaxazol and isoaxazopyridazines bearing 1,2,3-triazole moiety, Acta Polonica Pharm. - Drug Res. (2019) 76, doi:10.3233/apd-103101.
[21] H.R.M. Rashdan, H.M.F. Roaiya, Z.A. Muhammad, J. Wietrzyk, M. Milczarek, A.M.M. Soliman, Design, efficient synthesis, mechanism of reaction and anti-proliferative activity against cancer and normal cell lines of a series of fused pyrimidine derivatives, Acta Polonica Pharm. - Drug Res. (2018) 75.
[22] S. Dey, S. Johri, M. Abirami, B.K. Kumar, D. Tararemi, N. Basilo, R. Bal-Anoue, K.V.G.C. Sekhar, S. Murugesan, Search for structurally diverse heterocyclic analogs as dual-acting antimarial and antileishmanial agents: an overview, Eur. J. Med. Chem. (Rep. 2022) 100031.
[23] S. Dallakyan, A. Olson, J. small-molecule library screening by docking with PyRx, in: Chemical Biology, 1263, springer, 2015, pp. 243–250. ISBN 9780123444747.
[24] H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.A. Bhat, H. Weisg, L. Shindyalov, Bourne PE The protein data bank, Nucleic Acids Res. 28 (2000) 235–242, doi:10.1093/nar/28.1.235.
[25] N.M. O’Boyle, M. Banck, C.A. James, T. Vandermeersch, G.R. Hutchison, Open Babel: an open chemical toolbox, J. Cheminform. 3 (2011) 113, doi:10.1039/C4CS00051E.
[26] A.K. Rappé, C.J. Casewit, K.S. Colwell, W.A. Goddard, W.M. Skiff, UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations, J. Am. Chem. Soc. 114 (1992) 10024–10035, doi:10.1021/ja001051a.
[27] H.R. Rashdan, A. Shehadi, H. Abdelmonsef, A. Synthesis, anticaner evaluation, computer-aided docking studies, and ADMET prediction of 1,2,3-triazolyl-pyridine hybrids as human aurora B kinase inhibitors, ACS Omega 6 (2021) 1445–1455, doi:10.1021/acsomega.0c03516.
[28] I.A. Shehadi, H.R.M. Rashdan, A.H. Abdelmonsef, Homology modeling and virtual screening studies of antigen MLAIA-42 protein: identification of novel drug candidates against Leukemia—an in silico approach, Comput. Math. Methods Model. (2020) 2020.
[29] M. El-Naggar, M.E. Mohamed, A.M. Mosalam, W. Salem, H.R. Rashdan, A.H. Abdelmonsef, Synthesis, characterization, antibacterial activity, and computer-aided design of new quinazolin-2,4-dione derivatives as potential inhibitors against vibrio cholerae, Evol. Bioinform. 16 (2020) 117654319897595, doi: 10.1177/117654319897595.